Corporate Banner
Satellite Banner
Molecular & Clinical Diagnostics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Metabolon’s Quantose™ IR Test Featured in Five Poster Presentations at 2012 ADA Meeting

Published: Tuesday, June 12, 2012
Last Updated: Tuesday, June 12, 2012
Bookmark and Share
Clinical data demonstrate test’s effectiveness in stratifying prediabetic patients based on insulin resistance levels.

Metabolon, Inc. has announced that the clinical utility of the Company’s lead diagnostic product Quantose™ IR will be featured in five poster presentations at the 72nd Annual Scientific Sessions of the American Diabetes Association (ADA) being held June 8-12 in Philadelphia.

Quantose IR is a fasting blood test to measure insulin resistance (IR). The test measures levels of three novel non-glycemic biomarkers and insulin to detect prediabetes earlier and with greater sensitivity than traditional glycemic markers such as glucose and Hemoglobin A1C.

“This marks our fourth consecutive ADA annual meeting and our expanded presence this year reflects our Company’s continued focus on developing diagnostic tests related to metabolic disease,” said John Ryals, President and CEO of Metabolon.

Ryals continued, “As insulin resistance is known to precede Type 2 diabetes by up to 10 years, Quantose IR offers clinicians a tool for identifying patients at greatest risk for disease progression long before glycemic markers show evidence of dysregulation. Clinicians seeking to intervene in this high-risk group will be provided unique pathophysiological insight helpful in tailoring treatments to individual patients. Our Quantose IR test also provides a useful therapeutic monitoring tool to complement traditional markers in gauging treatment effectiveness due to its non-glycemic markers tracking so closely with changing insulin sensitivity.”

The following five abstracts related to Metabolon’s ongoing research and development efforts associated with Quantose IR will be featured at the ADA meeting:

“Early metabolic markers of the development of dysglycemia and Type 2 diabetes and their physiological significance”
• Alpha-hydroxybutyrate (AHB) and linoleoyl-glycerophosphocholine (L-GPC) are described as novel circulatory markers of insulin resistance, with clinical outcome data demonstrating their predictive risk to prediabetes and Type 2 diabetes and response to intervention.

Additional studies are presented that examine the Quantose IR biomarker’s physiological significance such as their bioactivity on insulin secretion. Abstract # 1600-P, to be presented by Dr. Walter Gall during the Monday, June 11th 12-2pm poster session.

“Pioglitazone improves insulin sensitivity by modulating novel biomarkers in impaired glucose tolerance” (Audio poster tour)
• Top-ranking insulin sensitivity biomarkers are measured in the T2D prevention study ACT NOW. The purpose of the study was to describe the response of the novel Quantose IR metabolites and its algorithm IR signature to pioglitazone pharmacotherapy and provide context of these observations in a diabetes prevention clinical setting.

Abstract # 1182-P, to be presented by Dr. Walter Gall during the Saturday, June 9th 11:30am-1:30pm poster session and the Sunday, June 10th 12-1pm guided audio tour.
 
“Metabolomic profile associated with hepatic insulin resistance in nondiabetic subjects: results from RISC study” (Audio poster tour)
• Quantose IR metabolites AHB and L-GPC are associated with hepatic insulin resistance, non-alcoholic fatty liver disease and NASH, further validating the clinical importance of measuring these novel biomarkers associated with IR-related disease outcomes. Abstract # 1791-P, to be presented by Dr. Amalia Gastadelli during the Monday, June 11th 12-2pm poster session.

“Effect of aging and exercise on novel insulin sensitivity marker linoleoyl-glycerophosphocholine” (Audio poster tour)
• Lifestyle intervention study with sedentary IR subjects demonstrate the response of Quantose IR metabolites AHB and L-GPC to aerobic exercise and further show associations of L-GPC with aging.

Abstract # 714-P, to be presented by Dr. Jose de Jesus Garduno Garcia during the Monday, June 11th 12-2pm poster session and the Monday, June 11th 1-2pm guided audio tour.

“Genetic variants associated with diabetes related circulating metabolite levels and their role in type 2 diabetes and insulin sensitivity”
• Genome-wide association studies were carried out with the RISC and Botnia prospective studies to identify and validate associations of genes and metabolites related to glycine, the top-ranking amino acid related to insulin sensitivity and proximal to Quantose IR metabolite AHB biosynthesis. Abstract # 1526-P, to be presented by Dr. Weijia Xie during the Monday, June 11th 12-2pm poster session.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Metabolon Launches Strategic Outsourcing Programs Focused On Disease Metabolism
Metabolon’s partners will collaborate toward shared objectives through this program.
Monday, October 15, 2012
Metabolon Strengthens Metabolomics Leadership with Acquisition of Lipomics Technologies
Gains proprietary lipids technology platform and further opportunities for diagnostics, personalized medicine and commercial services.
Friday, August 03, 2012
Metabolon Awarded Analytical Methods Patent
The patented method enables the researcher to process, analyze and interpret data more efficiently.
Thursday, March 29, 2012
Metabolon Secures $13 Million in Series D Financing
New investor Keating Capital, Inc. joins existing investors including Sevin Rosen Funds, Aurora Funds, Harris & Harris Group, Syngenta Ventures, Fletcher Spaght and Fulcrum Financial Partners in the round.
Tuesday, August 30, 2011
Researchers Identifify Adenosine-Mediated Sickling in Sickle Cell Disease and Associated End Organ Damage
Application of non-targeted biochemical profiling (metabolomics) to a mouse model of sickle cell disease (SCD) revealed a detrimental role of adenosine signaling in SCD and suggested novel therapeutic targets. The study was carried out in collaboration with The University of Texas Health Science Center at Houston.
Tuesday, December 21, 2010
Metabolic Signatures Associated with Type 2 Diabetes have been Identified
Data from a non-targeted biochemical profiling platform was combined with data collected from targeted metabolomics platforms to identify metabolic signatures that are associated with Type 2 diabetes. The proof of concept study illustrates the value of using metabolomics to identify biochemical pathways affected by Type 2 diabetes.
Tuesday, November 30, 2010
Scientific News
Liquid Biopsies: Miracle Diagnostic or Next New Fad?
Thanks to the development of highly specific gene-amplification and sequencing technologies liquid biopsies access more biomarkers relevant to more cancers than ever before.
Review of the Analysis of Haemoglobin A1c for Diabetes Diagnostics
This paper aims to clarify methods, units, quality requirements, reference and cutoff limits for hemoglobin A1c (HbA1c) and ratio of blood glucose/HbA1c on the basis of the results from Finnish quality control surveys by comparing them to the literature.
Colon Cancer Blocked in Mice
Case Western Reserve University Researchers block common type of colon cancer tumour in mice, laying groundwork for human clinical trial.
Drug - Gene 'One-Two' Punch Against Cancer
Researchers identify gene-drug combinations that, together, target and kill cancer cells while not targeting healthy cells.
Liquid Biopsies Treating Ovarian Cancer
Researchers have discovered a promising monitor and treat recurrence of ovarian cancer. Detecting cancer long before tumours reappear.
72% Rise in Metastatic Prostate Cancer
Over the 2003-2013 period metastatic cancer has increased by an average of 72%, this could be caused by lax screening, more aggressive disease or both.
Lab-Tested Diagnosis Needed When Treating Persistent Diarrhea
New PCR multiplex method makes lab testing more effective.
Biomarker for Multiple Sclerosis Detection Discovered
Winthrop-University Hospital researchers discover biomarker for multiple sclerosis detection.
Scientists Link Bipolar Disorder to Unexpected Brain Region
Researchers from The Scripps Research Institute have found that gene within the brain’s striatum could be linked to biopolar disorder.
Liquid Biopsies: DNA Size Matters
Study finds circulating tumour DNA can be distinguished from healthy DNA through fragment size identification.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!